Drug intelligence / Profile preview

compound angelica injection

Development stage: Unknown
Lead developer: Wanbangde Pharmaceutical Group
Administration: Intramuscular

Overview

Compound Angelica Injection is a Traditional Chinese Medicine (TCM) injectable product developed by Wanbangde Pharmaceutical Group. It is formulated from extracts of *Angelica sinensis* (Danggui) and *Ligusticum chuanxiong* (Chuanxiong). The injection is primarily indicated for gynecological disorders, including irregular menstruation, dysmenorrhea, and postpartum abdominal pain, leveraging TCM principles of tonifying blood and promoting circulation. It is also used clinically for its analgesic effects in treating conditions like sciatica and other forms of neuralgia. The product is approved for marketing in China and is administered via intramuscular injection.

Other names: Compound Angelica InjectionFufang Danggui ZhusheyeCompound Angelica Sinensis Injection

Beyond the preview

Go deeper on compound angelica injection.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on compound angelica injection.

Explore the full profile